These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23568416)

  • 1. Access to cancer medications in low- and middle-income countries.
    Lopes Gde L; de Souza JA; Barrios C
    Nat Rev Clin Oncol; 2013 Jun; 10(6):314-22. PubMed ID: 23568416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of oncology medicines in low- and middle-income countries.
    Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
    Ann Oncol; 2014 Jan; 25(1):270-6. PubMed ID: 24356638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
    Ooms G; Forman L; Williams OD; Hill PS
    BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential medicines for pediatric oncology in developing countries.
    Mehta PS; Wiernikowski JT; Petrilli JA; Barr RD;
    Pediatr Blood Cancer; 2013 May; 60(5):889-91. PubMed ID: 23450774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing access to quality anticancer medicines in low- and middle-income countries: the experience of Uganda.
    Osinde G; Niyonzima N; Mulema V; Kyambadde D; Mulumba Y; Obayo S; Anecho E; Watera S; Constance M; Kadhumbula S; Orem J
    Future Oncol; 2021 Jul; 17(21):2735-2745. PubMed ID: 33855863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving access to high-cost cancer drugs in Latin America: Much to be done.
    Ruiz R; Strasser-Weippl K; Touya D; Herrero Vincent C; Hernandez-Blanquisett A; St Louis J; Bukowski A; Goss PE
    Cancer; 2017 Apr; 123(8):1313-1323. PubMed ID: 28182258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Humanitarian Donations in Decreasing Preventable Mortality From Cancer in Low-Income Countries: Models to Improve Access to Life-Saving Medicines.
    Garcia-Gonzalez P; Lopes G; Schwartz E; Shulman LN
    J Glob Oncol; 2018 Jul; 4():1-3. PubMed ID: 30084718
    [No Abstract]   [Full Text] [Related]  

  • 9. Drugs are scarce as mix of programs aims to ease access.
    Brower V
    J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
    [No Abstract]   [Full Text] [Related]  

  • 10. Rising Cancer Drug Prices: What Can Low- and Middle-income Countries Do?
    Blanco-García E; Ledón N; Lage-Dávila A
    MEDICC Rev; 2018 Oct; 20(4):35-39. PubMed ID: 31242170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of cancer care and control in countries of low and middle income: a call to action.
    Farmer P; Frenk J; Knaul FM; Shulman LN; Alleyne G; Armstrong L; Atun R; Blayney D; Chen L; Feachem R; Gospodarowicz M; Gralow J; Gupta S; Langer A; Lob-Levyt J; Neal C; Mbewu A; Mired D; Piot P; Reddy KS; Sachs JD; Sarhan M; Seffrin JR
    Lancet; 2010 Oct; 376(9747):1186-93. PubMed ID: 20709386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income Countries.
    Barr R; Robertson J
    Pediatr Blood Cancer; 2016 Feb; 63(2):287-91. PubMed ID: 26375626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments.
    Aguiar PN; Adashek JJ; Roitberg F; Noia Barreto CM; Del Giglio A; Lopes GL
    Value Health Reg Issues; 2019 Dec; 20():47-50. PubMed ID: 30856543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the time come for metronomics in low-income and middle-income countries?
    André N; Banavali S; Snihur Y; Pasquier E
    Lancet Oncol; 2013 May; 14(6):e239-48. PubMed ID: 23639324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A global comparison regarding patient access to cancer drugs.
    Jönsson B; Wilking N
    Ann Oncol; 2007 Apr; 18 Suppl 3():iii1-iii77. PubMed ID: 17494969
    [No Abstract]   [Full Text] [Related]  

  • 17. Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region.
    Salmasi S; Lee KS; Ming LC; Neoh CF; Elrggal ME; Babar ZD; Khan TM; Hadi MA
    BMC Cancer; 2017 Dec; 17(1):903. PubMed ID: 29282008
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.